Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 223

Similar articles for PubMed (Select 7895352)

1.

Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study.

Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE, et al.

Circulation. 1995 Apr 1;91(7):1952-8.

2.

Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators.

Shahar E, Folsom AR, Salomaa VV, Stinson VL, McGovern PG, Shimakawa T, Chambless LE, Wu KK.

Circulation. 1996 Jun 1;93(11):1970-5.

3.

Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors.

Katz RJ, Hsia J, Walker P, Jacobs H, Kessler C.

Am J Cardiol. 1996 Oct 15;78(8):876-80.

PMID:
8888658
4.

Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women.

Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH.

Am J Epidemiol. 1996 Jan 15;143(2):159-66.

5.

Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.

Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO 3rd.

N Engl J Med. 1997 Mar 6;336(10):683-90.

6.

Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.

Lindoff C, Peterson F, Lecander I, Martinsson G, Astedt B.

Maturitas. 1996 May;24(1-2):43-50.

PMID:
8794433
7.

Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels.

Koh KK, Son JW, Ahn JY, Lee SK, Hwang HY, Kim DS, Jin DK, Ahn TH, Shin EK.

Int J Cardiol. 2001 Nov;81(1):43-50.

PMID:
11690664
8.
9.

Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.

Pradhan AD, LaCroix AZ, Langer RD, Trevisan M, Lewis CE, Hsia JA, Oberman A, Kotchen JM, Ridker PM.

Circulation. 2004 Jul 20;110(3):292-300. Epub 2004 Jul 6.

10.

Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy.

Falcó C, Tormo G, Estellés A, España F, Tormo E, Gilabert J, Velasco JA, Aznar J.

Haematologica. 2001 Jan;86(1):92-8.

11.

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3071-8.

12.

Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.

Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson BB.

Stroke. 1996 Jun;27(6):1066-71.

13.

Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group.

Pasquali R, Vicennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O, Labate AM.

Metabolism. 1997 Jan;46(1):5-9.

PMID:
9005961
14.

Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy.

Nozaki M, Ogata R, Koera K, Hashimoto K, Nakano H.

Climacteric. 1999 Jun;2(2):124-30.

PMID:
11910665
16.

Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.

DeSouza CA, Jones PP, Seals DR.

Arterioscler Thromb Vasc Biol. 1998 Mar;18(3):362-8.

17.

Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.

Grancha S, Estellés A, Tormo G, Falco C, Gilabert J, España F, Cano A, Segui R, Aznar J.

Thromb Haemost. 1999 Apr;81(4):516-21.

PMID:
10235431
18.

Association of blood pressure with fibrinolytic potential in the Framingham offspring population.

Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, D'Agostino RB, Wilson PW, Levy D.

Circulation. 2000 Jan 25;101(3):264-9.

19.

Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk.

Tofler GH, D'Agostino RB, Jacques PF, Bostom AG, Wilson PW, Lipinska I, Mittleman MA, Selhub J.

Thromb Haemost. 2002 Nov;88(5):799-804.

PMID:
12428097
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk